11:19 AM EDT, 05/28/2024 (MT Newswires) -- Novo Nordisk ( NVO ) has told US Senate Heath Committee Bernie Sanders it only keeps about 60% of the list price of its weight loss and diabetes drugs Ozempic and Wegovy in the US after the rebates and fees paid to middlemen in the country's health care system, Bloomberg reported Tuesday, citing a letter sent to the lawmaker on Friday.

The company said in the letter it's prepared to work with US lawmakers to address "systemic issues so that everyone who can benefit from its medicines is able to get them," according to the report.

The company also said that it's not fair to look only at what it costs to produce the drugs and their price to payers because it invested billions of dollars up-front to develop them, Bloomberg reported.

The Senate Health Committee began a probe into Novo's pricing last month.

Novo told MT Newswires in a statement "everything we can share is in the Bloomberg article."

Sanders' office didn't immediately reply to a request for comment by MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 133.87, Change: -2.17, Percent Change: -1.60